NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

Wegovy is now positioned as the first and only GLP-1 treatment.

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Discover how weight-loss drugs like Wegovy and Mounjaro are being tested for a range of health conditions including alcohol addiction, Alzheimer's disease, and cardiovascular issues. Learn about their ...

Landmark Science today announced its presence at International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, in collaboration with Innovaccer, set to take place August 22–26 in ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...

The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated ...

A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...